Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

nses 2,398 2,663 9,465 5,864 ------- -------- Other income (expense) 29 297 120 88 ------- -------- Loss for the period before taxes and extraordinary gain 2,369 2,366 9,345 5,776 Income tax expense (recovery) 16 (2,515) 12 (2,100) ------- -------- Loss (income) for the period before extraordinary gain 2,385 (149) 9,357 3,676 Extraordinary gain - 4,428 - 4,428 ------- -------- Net loss (income) 2,385 (4,577) 9,357 (752) Redeemable convertible preferred share accretion - 417 - 1,973 ------- -------- Loss (income) attributable to common shareholders $ 2,385 $(4,160) $ 9,357 $ 1,221 Condensed Balance Sheets (unaudited) (in thousands) September 30, December 31, 2009 2008 Assets: Cash, cash equivalents and short term investments $12,473 $12,419 Amounts and investment tax credit receivable 31 1,243 Prepaid and other current assets 1,487 587 Property, equipment and other assets 593 541 ------- ------- Total assets $14,584 $14,790
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., This release is available in German . ,...cation cards: RFID tags (Radio Frequency Identific...ryday life. They make it possible to label objects... frequency. The appropriate scanner can read and p...ls can be affixed to goods under production condit...
(Date:11/24/2009)..., The New York investment...Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible...investor. The private placement was arranged by KT...d advisor. , New York (PR... investment bank KTA Capital, LLC ("KTA Capit...
(Date:11/24/2009)...,, REYKJAVIK,Iceland,November24/PRNewswire-F...yannouncedthatithasreceivednoticefrom,theNasdaqSto...,suspendedasofNovember30,2009andaForm25-NSEwillbef...illremovedeCODE,scommonstock,fromlistingonNasdaq,u...lificationsPanel.Thecompanyhasfiledsuchanappeal,wh...
(Date:11/24/2009)...,, REYKJAVIK,Iceland,November24/PRNewswire-F...yannouncedtheapprovalofallofits,"firstday"motionsb...he"BankruptcyCourt").deCODElastweekfiledavoluntary...ankruptcyCodewiththe,BankruptcyCourt. , Theor...tinue,tooperateitsbusinessduringtheChapter11procee...
Breaking Biology Technology:Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today ... accomplishments., For the second quarter ended J...loss of $7.4 million, or $0.18 per share, compared..., for the same period in 2007.,As of June 30, 2008...tments,of $64.3 million., Revenues for the second...
... Operating Earnings Down 6%, GAAP Operating Earnin...GAAP Diluted EPS Down 19%, PALO ALTO, Calif., Jul... third fiscal quarter 2008 revenues of,$244.4 mill...s of $227.1,million in the third quarter of fiscal...includes environmental, food and energy) and life ...
...uman Genome,Sciences, Inc. (Nasdaq: HGSI ) today ...o discuss its financial results for the quarter en...e disclosed on Wednesday, July 30,2008, after the ...m.com/cgi-bin/prnh/20080416/HGSLOGO ), The confe... will be,held on Wednesday, July 30, 2008 at 5:00 ...
Other Biology Technology:Sangamo BioSciences Reports Second Quarter 2008 Financial Results 2Sangamo BioSciences Reports Second Quarter 2008 Financial Results 3Sangamo BioSciences Reports Second Quarter 2008 Financial Results 4Sangamo BioSciences Reports Second Quarter 2008 Financial Results 5Sangamo BioSciences Reports Second Quarter 2008 Financial Results 6Sangamo BioSciences Reports Second Quarter 2008 Financial Results 7Sangamo BioSciences Reports Second Quarter 2008 Financial Results 8Varian, Inc. Reports Third Quarter 2008 Results 2Varian, Inc. Reports Third Quarter 2008 Results 3Varian, Inc. Reports Third Quarter 2008 Results 4Varian, Inc. Reports Third Quarter 2008 Results 5Varian, Inc. Reports Third Quarter 2008 Results 6Varian, Inc. Reports Third Quarter 2008 Results 7Varian, Inc. Reports Third Quarter 2008 Results 8Varian, Inc. Reports Third Quarter 2008 Results 9Varian, Inc. Reports Third Quarter 2008 Results 10Varian, Inc. Reports Third Quarter 2008 Results 11Varian, Inc. Reports Third Quarter 2008 Results 12Varian, Inc. Reports Third Quarter 2008 Results 13Varian, Inc. Reports Third Quarter 2008 Results 14Varian, Inc. Reports Third Quarter 2008 Results 15Varian, Inc. Reports Third Quarter 2008 Results 16Varian, Inc. Reports Third Quarter 2008 Results 17Varian, Inc. Reports Third Quarter 2008 Results 18Varian, Inc. Reports Third Quarter 2008 Results 19Varian, Inc. Reports Third Quarter 2008 Results 20Varian, Inc. Reports Third Quarter 2008 Results 21Varian, Inc. Reports Third Quarter 2008 Results 22Varian, Inc. Reports Third Quarter 2008 Results 23Varian, Inc. Reports Third Quarter 2008 Results 24Varian, Inc. Reports Third Quarter 2008 Results 25Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results 2
(Date:11/23/2009)...RE, Calif. - By producing some of the highest reso...faces, scientists have a deeper understanding how ...research may lead to a new treatment for kidney st...ppears in the Nov. 23 online edition of the journa... , explores how peptides interact with mineral sur...
(Date:11/23/2009)...MINGHAM, Ala. A new study by University of Alabam...mass index (BMI) and co-existing medical condition...ival observed among African-Americans compared to ...s published online Nov. 23 in Cancer , a journal ...dicates that although BMI and co-morbidity are ind...
(Date:11/23/2009)...GN, Ill. Two new studies reveal in unprecedented ...ules to assemble new proteins and guide them towar...es used molecular dynamics flexible fitting (MDFF)...wo prominent molecular partners. , The first st...iences , concerns the intimate signaling between t...
Breaking Biology News(10 mins):Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Hot microbes cause groundwater cleanup rethink 9979 1Hot microbes cause groundwater cleanup rethink 9979 2Symposium marks 20th anniversary of Theoretical and Computational Biophysics Group 9975 1Symposium marks 20th anniversary of Theoretical and Computational Biophysics Group 9975 2Symposium marks 20th anniversary of Theoretical and Computational Biophysics Group 9975 3Symposium marks 20th anniversary of Theoretical and Computational Biophysics Group 9975 4New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 1New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 2New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 3New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 4New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 5New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 6
...lands: Consumers are five times more likely to ide...fic light nutrition labels than when labels presen...entage of the recommended daily nutrient intake ea...overnments are trying to improve the quality of nu...in supermarkets by adding labels to the front of f...
...NY) Inappropriate use of camphor-containing produ...seizures in young children, according to a new stu...dicine of Yeshiva University. The study, published...efforts to educate communities about the hazards o...camphor products. , Camphora naturally occurring ...
...of influenza infection severity have been identifi... find most of these markers, described in the open...the current swine-flu strain. , Jonathan Allen an...ratory, America, published their analysis identify...emic flu strains two weeks ago. They have since st...
Other Biology News:Consumers more likely to identify healthy food using traffic light nutrition labels 2Camphor-containing products may cause seizures in children 2
Rabbit Anti-melatonin Antibody, Unconjugated from Cell Sciences
Rabbit Anti-DDDDK Tag Antibody, Agarose Conjugated from MBL International
Goat Anti-FbxL7 Polyclonal Antibody, Unconjugated from GeneTex
Anti-PERK, phospho (Thr980) Antibody, Unconjugated from Cell Signaling Technology
Biology Products: